Ruth O’Regan, MD; Joyce A. O’Shaughnessy, MD; Hope S. Rugo, MD, FASCO; and Debu Tripathy, MD, provide insight regarding recent updates from key clinical trials on the management of metastatic 

Data from the following clinical trials are discussed:

Latest findings from the phase 2 SUMMIT basket trial on neratinib plus trastuzumab plus fulvestrant for HR-positive MBC with activating 

 mutations (Jhaveri K, et al. 2020 SABCS. Poster PD1-05).

-positive metastatic breast cancer patients with central nervous system disease at baseline: Findings from the phase 3 NALA trial (Saura C, et al. 2020 SABCS. Poster PD13-09).

Neratinib + capecitabine sustains health-related quality of life (HRQoL) while improving progression-free survival (PFS) in patients with 

+ metastatic breast cancer and ≥2 prior HER2-directed regimens (Moy B, et al. 2020 SABCS. Poster PS9-02).

Final analysis of PERTAIN: A randomized, 2-arm, open-label, multicenter phase 2 trial assessing the efficacy and safety of first-line pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in patients with 

-positive and hormone receptor–positive metastatic or locally advanced breast cancer (Arpino G, et al. 2020 SABCS. Poster PD3-02).

A randomized, open-label, phase 3 trial of pertuzumab re-treatment in 

-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study (Yamamoto Y, et al. 2020 SABCS. Poster PD3-11).

Updated results from DESTINY-Breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in 

-positive metastatic breast cancer (Modi S, et al. 2020 SABCS. Poster PD3-06).

Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: A 2-part, phase 1b, multicenter, open-label study (Hamilton E, et al. 2020 SABCS. Poster PD3-07).

Tucatinib vs placebo in combination with trastuzumab and capecitabine for patients with locally advanced unresectable or 

-positive metastatic breast cancer (HER2CLIMB): Outcomes by hormone receptor status (Hamilton E, et al. 2020 SABCS. Poster PD3-08).

Impact of tucatinib on health-related quality of life in patients with HER2+ metastatic breast cancer with stable and active brain metastases (Wardley A, et al. 2020 SABCS. Poster PD13-04).

Videos

Updated Data for Metastatic HER2+ Breast Cancer

A review of data presented at the 2020 San Antonio Breast Cancer Symposium (SABCS) examining the development and validation of prognostic tools for early stage 

First results from a phase 3 randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1–3 positive nodes, hormone receptor–positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPONDER) (Kalinsky K, et al. 2020 SABCS. Poster GS3-00).

Primary outcome results from the WSG-ADAPT HR+/HER2- trial: Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0–3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy (Harbeck N., et al. 2020 SABCS. Poster GS4-04).

Continued efficacy of neratinib in patients with 

-positive early stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial (Holmes FA, et al. 2020 SABCS. Poster PD3-03).

Bringing diarrhea under CONTROL: Dose escalation reduces neratinib-associated diarrhea and improves tolerability in 

-positive early stage breast cancer (Ruiz-Borrego M, et al. 2020 SABCS. Poster PS13-20).

The DAPHNe trial: A feasibility study of chemotherapy de-escalation based on response to neoadjuvant paclitaxel-HP (THP) in 

-positive breast cancer (Waks AG, et al. 2020 SABCS. Poster PD3-05).

Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in 

-positive early breast cancer: Analysis from the ALTTO (BIG 2-06) trial (Lambertini M, et al. 2020 SABCS. Poster PD3-04).

Prognostic Tools for Early-Stage HER2+ Breast Cancer 

Breast cancer experts discuss the evolution of HER2-targeted treatments, including margetuximab, trastuzumab, tucatinib, and neratinib, along with unmet needs in patients with 

Joyce O'Shaugnessy, MD, Texas Oncology

Articles

Updated Data for Metastatic HER2+ Breast Cancer

Prognostic Tools for Early-Stage HER2+ Breast Cancer

Current Treatment Landscape for HER2+ Breast Cancer